FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation
- 877 Downloads
Receptor tyrosine kinase pathways are potential therapeutic targets in gastric adenocarcinoma patients. We evaluated HER2 and cMet protein expression, and FGFR2 gene amplification to assess their prognostic significance, and downstream mediators pS6 and pERK for their potential utility as pharmacodynamic biomarkers in patients with gastric adenocarcinoma. Tissue microarrays were constructed from resection samples of 184 patients who underwent surgery for gastric/gastro-oesophageal junction adenocarcinoma. Tissue cores were obtained from the tumour body (TB), luminal surface (LS) and invasive edge (IE), and immunohistochemical and fluorescence in situ hybridisation (FGFR2) analysis was performed. FGFR2 amplification was identified in 2 % of cases and associated with worse survival (P = 0.005). HER2 overexpression was observed in 10 % of cases and associated with increased survival (P = 0.041). cMet overexpression was observed in 4 % of cases and associated with worse survival (P < 0.001). On multivariate analysis, only cMet retained significance (P = 0.006). pS6 and pERK expression were observed in 73 % and 30 % of tumours, respectively, with no association with survival. HER2 (P = 0.004) and pERK (P = 0.001) expression differed between tumour regions with HER2 expression increased in the LS compared with the TB and IE. These findings confirm subpopulations in gastric adenocarcinoma with poor outcome that may benefit from specific therapeutic strategies. However, we found heterogeneous HER2, pS6 and pERK overexpression, which presents challenges for their use as predictive biomarkers in gastric biopsies. The potential downstream pharmacodynamic markers pS6 and pERK were expressed across tumour regions, providing evidence that resections and biopsies would yield comparative results in clinical trials.
KeywordsGastric adenocarcinoma FGFR2 HER2 cMet Tissue microarray
We would like to thank the FGFR2 FISH analysis team at AstraZeneca: Laura Blockley, Grace Harrod and James Stevens, and we also thank Claire Routley PhD, from Mudskipper Business who provided medical writing assistance funded by AstraZeneca. This study was sponsored by AstraZeneca. Additionally, Catharine West was supported by Experimental Cancer Medicine Centre funding.
Conflict of interest
G Betts, H Valentine, S Pritchard, R Swindell, E Griffiths, Ian Welch and C West have no conflicts of interest to disclose. V Williams, S Morgan and C Womack are full-time employees of AstraZeneca and have AstraZeneca shares.
- 4.Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRefGoogle Scholar
- 5.Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673–684PubMedCentralPubMedCrossRefGoogle Scholar
- 8.Xie L, Su X, Zhang D, Tang L, Xu J, Wang M, Yin L, Zhang J, Ye K, Wang Z, Kilgour E, Ji Q (2011) AZD4547, a potent and selective inhibitor of FGF-receptor tyrosine kinases 1, 2 and 3, inhibits the growth of FGF-receptor 2 driven gastric cancer models in vitro and in vivo. Proc Am Assoc Cancer Res 52:abst 1643Google Scholar
- 9.Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, Chen Z, Wilson CJ, Bordas V, Le Douget M, Gaither LA, Borawski J, Monahan JE, Venkatesan K, Brummendorf T, Thomas DM, Garcia-Echeverria C, Hofmann F, Sellers WR, Graus Porta D (2012) FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2:1118–1133PubMedCrossRefGoogle Scholar
- 10.Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K, Dong Z, Zhu G, Qian Z, Tang L, Zhan P, Ji Q, Kilgour E, Smith PD, Brooks AN, Thomas RK, Gavine PR (2012) Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res 18:6658–6667PubMedCrossRefGoogle Scholar
- 11.Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T (2012) AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 72:2045–2056PubMedCrossRefGoogle Scholar
- 13.Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K, Mohri Y, Inoue Y, Goel A, Kusunoki M (2012) Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 130:2912–2921PubMedCrossRefGoogle Scholar
- 15.Cho H, Zhang X, Jung M, Kwon W, Jung J, Jeung H, Roh JK, Chung HC, Rha SY (2010) C-met as a therapeutic target for metastatic potential of gastric cancer. J Clin Oncol 28(15S):abst e14568.Google Scholar
- 17.Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25:1517–1524PubMedGoogle Scholar
- 18.Zeng W, Yan L, Peek V, Wortinger M, Tetreault J, Xia J, Chow C-K, Manro JR, Stephens JR, Weir SN, Tang Y, Vaillancourt P, Lu J, Yan BS, Liu L (2012) c-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer. Cancer Res 72(8 Suppl 1):abst 2734Google Scholar
- 20.Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Muller M, Langer O, Wacheck V (2011) Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18 F]FLT uptake. Clin Cancer Res 17:5322–5332PubMedCrossRefGoogle Scholar
- 22.Martin-Richard M, Tibau A, Ferre M, Castillo-Martin M, Colomer A, Erill N, Sancho F, Gich I, Barnadas A (2012) MEK/ERK pathway characterisation and its prognostic implication in gastric cancer (GC). J Clin Oncol 30(15S):abst e14552Google Scholar
- 27.Ilyas M, Grabsch H, Ellis IO, Womack C, Brown R, Berney D, Fennell D, Salto-Tellez M, Jenkins M, Landberg G, Byers R, Treanor D, Harrison D, Green AR, Ball G, Hamilton P (2013) Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology 62:827–839PubMedCrossRefGoogle Scholar
- 30.Kilgour E, Su X, Zhan P, Gavine P, Morgan S, Womack C, Jung E-J, Bang Y-J, Im S-A, Kim W, Grabsch H (2012) Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts. J Clin Oncol 30(15S):abst 4124Google Scholar
- 31.Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273–278PubMedCrossRefGoogle Scholar
- 42.Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang LH, Ji JF, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q (2013) FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 19:2572–2583PubMedCrossRefGoogle Scholar